Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 16, 2023; 11(32): 7911-7919
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7911
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7911
Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports
Lu Zhang, Ming-Jin Xu, Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Ai-Xin Gao, Department of Radiology, The Affiliated hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Yu-Lu He, Department of Pathology, Peking University People's Hospital, Qingdao 266003, Shandong Province, China
Hai-Jun Lu, Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong Province, China
Author contributions: Zhang L contributed to manuscript writing and editing; Gao AX and He YL contributed to data collection; Xu MJ contributed to data analysis; Lu HJ contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Jun Lu, PhD, Professor, Radiation Oncology, The Affiliated Hospital of Qingdao University, Haier Road, Qingdao 266000, Shandong Province, China. lhj82920608@163.com
Received: September 24, 2023
Peer-review started: September 24, 2023
First decision: October 9, 2023
Revised: October 23, 2023
Accepted: November 2, 2023
Article in press: November 2, 2023
Published online: November 16, 2023
Peer-review started: September 24, 2023
First decision: October 9, 2023
Revised: October 23, 2023
Accepted: November 2, 2023
Article in press: November 2, 2023
Published online: November 16, 2023
Core Tip
Core Tip: SMARCB1/INI-1 deficient sinonasal carcinoma (SDSC) is a rare carcinoma with a poor prognosis and no standard treatment guidelines. Currently, the most effective treatment option is surgery followed by adjuvant chemoradiotherapy. Here, we present two SDSC patients with complicated consultation experiences. The patients differed in treatments and prognoses, and there was no indications of local recurrence or distant metastases in patient with immunotherapy. We also review the literature on SDSC treatment. This first report on immunotherapy in SDSC provides a unique perspective on treatments for this rare tumor.